Medtronic Starts International Market Launch And U.S. Clinical Trial Of Endurant Stent Graft Expanding the application of endovascular aortic repair around the world, Medtronic, Inc. (NYSE: MDT), announced two major milestones: the international market launch of the Endurant Abdominal Stent Graft System and the first implants of this next-generation medical device in the U.S. clinical trial.
Source: www.medicalnewstoday.comOLIGOMERIX Funded By The ADDF To Evaluate Compounds Active Against Tau Oligomers, A Novel Target For Therapeutic Development OLIGOMERIX, Inc. announced receipt of a program related investment of $100K from the Alzheimer's Drug Discovery Foundation (ADDF). The focus of the program is to select compounds using its proprietary Alzheimer's disease (AD) screening assays active against tau oligomers, and to evaluate these compounds in a tauopathy mouse model. The work will be done in collaboration with Dr.
Source: www.medicalnewstoday.comAggressive Treatment Of Childhood Eczema Could Help Prevent Asthma, Says New Study The study, published online in the Journal of Allergy and Clinical Immunology, calls for trials of aggressive therapies against childhood eczema in attempt to reduce the incidence of asthma in later life.
Source: www.medicalnewstoday.comFDA Grant AMDL Clearance To Market THE AMDL-ELISA DR-70(R) (FDP) Blood Test For Monitoring Colorectal Cancer AMDL, a leading vertically integrated bio-pharmaceutical company with operations in China and the US, announced today the US Food and Drug Administration (FDA) has issued a letter of substantial equivalence to an existing predicate device and granted clearance to market the AMDL-ELISA DR-70� (FDP
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 AM
